STAAR Surgical Company (STAA) Stock Analysis & AI Equity Report

Medical - Instruments & Supplies USD Explore free reports

STAAR Surgical Company (STAA) overview

STAAR Surgical Company (STAA) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 239m and operating profit of USD -91.7m; the year-end share price was 23.60 USD and market capitalisation was USD 1,166m. STAAR Surgical Company is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get STAAR Surgical Company's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 344mFY 2025
Share price23.60 USDFY 2025 year end
RevenueUSD 239mFY 2025
Operating profitUSD -91.7mFY 2025
Net earningsUSD -80.4mFY 2025
Market capitalisationUSD 1,166mFY 2025 year end

About STAAR Surgical Company

STAAR Surgical designs, develops, manufactures, and sells implantable eye lenses and delivery systems used to place them. Its principal products are Implantable Collamer Lenses, including the EVO family for myopia and Visian ICL for hyperopia; some models also address astigmatism. These lenses are used in refractive surgery and are sold through company representatives and independent distributors across its markets.

Generate the STAAR Surgical Company report

STAAR Surgical Company is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for STAAR Surgical Company and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on STAAR Surgical Company

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.